DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DaVita Inc. (DVA) reported Q2 2026 adjusted EPS of $4.02, up 36.3% year over year and 0.3% above the Zacks Consensus. Revenue rose 5.2% to $3.55 billion, slightly above consensus. Gross margin fell 38 bps to 32.7%. The stock was down about 7.1% in pre-market after the results.
How this was made
The 30-second read
Why it matters
The key trading tension is that fundamentals improved year over year, yet sequential profitability metrics deteriorated, and the market responded with a roughly 7% pre-market decline. The revised 2026 outlook keeps RPT growth modest (1%-2%) and EPS guidance in a defined range, making margin trajectory the main swing factor for the next few quarters.
Market read
This is a post-earnings repricing story: investors are trading the gap between headline beats and weaker sequential profitability, with guidance framed around modest RPT growth and a defined EPS range.
What to watch
The article notes operating cash flow strength and ongoing share repurchases, which can cushion downside even if margins are pressured near term.
Background
DaVita’s Q2 2026 results included an EPS and revenue beat, but management attributed sequential RPT weakness to lower commercial mix from declining ACA enrollment and lower sequential phosphate binder contribution.
Ticker impact
DaVita reported Q2 2026 adjusted EPS of $4.02 and revenue of $3.55B, but gross margin fell and the stock dropped about 7.1% pre-market.
Near-term downside bias likely persists until investors see margin stabilization or RPT re-acceleration.
The article cites specific margin contraction (gross margin -38 bps) and sequential RPT decline (-0.4%), alongside a large pre-market drop despite EPS/revenue beats.
Market effects
Dialysis providers may face renewed scrutiny on margin durability and reimbursement mix, especially around ACA enrollment and treatment mix.
Primarily impacts US healthcare services sentiment given the focus on US dialysis treatments and ACA-driven mix.
Limited direct global read-through, though integrated kidney care spend and international center counts provide some context for investors.
Counterpoint
Investors may be overreacting to sequential RPT and margin noise, since full-year adjusted EPS guidance remains intact and management highlighted dialyzer supply enabling expanded hemodialysis.
Key entities
- companyDaVita Inc.
Reported Q2 2026 adjusted EPS of $4.02, revenue of $3.55B, margin contraction, sequential RPT decline, and revised 2026 outlook; shares fell about 7.1% pre-market.
